Oku Digital Health launches platform linking eye-care data to drug development
Oku Digital Health has launched a digital health platform connecting more than 10,000 point-of-care locations with pharmaceutical research and clinical development. Its Harmony solution uses multimodal AI to analyze retinal imaging and clinical data, helping identify potential clinical trial participants, support site selection, and generate longitudinal real-world evidence across ocular, cardiovascular, renal, metabolic, and neurodegenerative diseases. The platform aims to improve trial recruitment, reduce screening inefficiencies, and expand the use of ophthalmic data in drug development.
Cigna Healthcare introduces Health Sense for personalized care support
Cigna Healthcare has introduced Health Sense, a personalized support model that connects members’ health needs, benefits, pharmacy coverage, costs, and previous interactions to deliver more relevant care guidance. The platform aims to help members navigate care options, identify in-network providers, understand costs, and access clinical support earlier, while keeping treatment decisions with patients and their providers. Expected to launch in early 2027, Health Sense will initially focus on oncology and cardiometabolic conditions, with Cigna projecting the model could reduce inefficient healthcare spending by 10% by 2030.
Click Therapeutics receives FDA clearance for schizophrenia digital therapeutic
Click Therapeutics has received FDA 510(k) clearance for Motivista (CT-155), a prescription digital therapeutic for adults with negative symptoms of schizophrenia, including low motivation, reduced pleasure, and social withdrawal. In the Phase III CONVOKE study, the smartphone-based treatment demonstrated a 62% relative improvement in negative symptom severity compared with digital control at 16 weeks, with no serious treatment-related adverse events reported. Designed to complement clinician-managed outpatient care and antipsychotic therapy, Motivista expands digital treatment options for a condition with limited targeted therapies.
